CKChikako Kaminaka

Chikako Kaminaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chikako Kaminaka has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy, Safety, and Predictive Value of Quantitative Histopathology in Picosecond Laser Therapy for Congenital Melanocytic Nevi: A Prospective Clinical Trial

    by Kayo Kunimoto, Chikako Kaminaka, Kyoko Muraoka, Tomoyuki Hara, Minako Tanaka, Masatoshi Jinnin, Yuki Yamamoto

    In this single‐arm prospective study, we evaluated the efficacy and safety of a 1064/532‐nm Nd:YAG picosecond laser for congenital melanocytic nevi (CMN) and investigated the association between clinical response and quantitative histopathologic findings. Thirteen Japanese patients with a median age of 4 years were enrolled and received up to five laser treatment sessions at 1‐ to 3‐month intervals. Clinical efficacy was primarily assessed using the Investigator Global Assessment (IGA) score at 3 months after treatment, supplemented by Melanin Index analysis and ImageJ‐based histopathologic quantification of nevus cell area fraction and melanin distribution. At the 3‐month follow‐up, 30.8% of patients achieved an IGA score of 5 (≥ 75% improvement), and 84.6% achieved an IGA score of 4 (50%–74% improvement) or higher. The Melanin Index decreased significantly ( p < 0.001); at 1 year, the group‐level mean remained significantly below baseline, although 3 of 13 patients had values above baseline. Histopathologic analysis showed a strong negative correlation between IGA score and nevus cell area fraction ( ρ = −0.849, p = 0.0002). In an exploratory multivariable analysis, nevus cell area fraction remained significantly associated with clinical outcome, whereas peak cumulative mean melanin area fraction was not. All participants experienced transient local treatment‐related adverse events; however, these resolved by the 3‐month follow‐up without treatment discontinuation or irreversible sequelae. These findings suggest that picosecond laser therapy may be a safe and effective minimally invasive treatment option for CMN and that clinical responsiveness may be more closely associated with nevus cell burden than with the depth‐related melanin distribution parameter. Pretreatment histopathologic evaluation of nevus cell area fraction may therefore be useful for predicting clinical response.

  • Clinical evaluation of needle‐free electronic pneumatic hyaluronic acid injection treatment for facial atrophic acne scars: A prospective, randomized comparative trial

    by Chikako Kaminaka, Mariko Sakata, Mana Nishiguchi, Kayo Kunimoto, Naoya Mikita, Masatoshi Jinnin, Koji Uede, Kensuke Tanioka, Yuki Yamamoto

    Acne scars are common but difficult to treat, and an effective new treatment strategy is desired. This prospective, split‐face randomized controlled trial was designed to compare the safety and efficacy of needle‐free electronic pneumatic hyaluronic acid injection (EPI‐HA) treatment for acne scars. Thirty Japanese subjects with moderate to severe facial atrophic acne scars underwent EPI‐HA treatment on a randomized side of their face. Three treatment sessions were carried out at 1‐month intervals, and the subjects were followed‐up for 3 months after the final treatment. Three months after the final treatment, 48.3% of treated sides met the criteria for success, compared with 0% for the control sides (P < 0.0001). Rolling type scars were much improved compared with boxcar types and icepick types. Satisfaction (or better) was reported by 55.2% of subjects at the 3‐month follow‐up after the final treatment, which was similar to the physicians' assessment. Three‐dimensional in vivo imaging analysis detected significant difference in scar reductions between the treated and control sides in the mean scar area, scar depth, and maximum depth of the biggest scar at 1 and 3 months after the final treatment (all P < 0.05). In conclusion, EPI‐HA treatment significantly improved rolling facial atrophic acne scars in our Japanese subjects, with minimal side effects.


  • Analysis of cytokine profiles in sera of single and multiple infantile hemangioma

    by Mariko Sakata, Kayo Kunimoto, Ami Kawaguchi, Yutaka Inaba, Chikako Kaminaka, Yuki Yamamoto, Nobuyuki Kakimoto, Tomohiro Suenaga, Daisuke Tokuhara, Masatoshi Jinnin

    Infantile hemangiomas (IH) are benign vascular tumors that are common in infancy. They vary in growth, size, location, and depth, and although most lesions are relatively small, approximately one fifth of patients have multiple lesions. Risk factors for IH include female sex, low birth weight, multiple gestation, preterm birth, progesterone therapy, and family history, but the mechanism that causes multiple lesions is unclear. We hypothesized that blood cytokines are involved as a cause of multiple IHs, and tried to prove this using sera and membrane arrays from patients with single and multiple IHs. Serum samples were obtained from five patients with multiple lesions and four patients with a single lesion, none of which had received any treatment. Serum levels of 20 cytokines were measured using human angiogenesis antibody membrane array. Four of the 20 cytokines (bFGF, IFN-gamma, IGF-I, and TGF-beta 1) were higher in the patients with multiple lesions than in those with single lesion, with statistically significant difference (p < 0.05). Notably, signal for IFN-gamma was evident in all cases with multiple IHs, but was absent in cases with single IH. Although not significant, there was mild correlation between IFN-gamma and IGF-I (r = 0.64, p = 0.065), and between IGF-I and TGF-beta 1 (r = 0.63, p = 0.066). bFGF levels were strongly and significantly correlated with the number of lesions (r = 0.88, p = 0.0020). In conclusion, blood cytokines could act as a cause of multiple IHs. This is a pilot study with a small cohort, so further large-scale studies are necessary.


  • ESDR616 - yRNA4 up-regulation induces collagen expression in scleroderma cultured dermal fibroblasts

    by Masatoshi Jinnin, Chikako Kaminaka, Yuki Yamamoto

    YRNA is an essential factor for chromosomal DNA replication and has a functional role. Four yRNA subtypes have shown some diagnostic and prognost | POSTER

  • Open Access

    Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage

    by Kayoko Tabata, Chikako Kaminaka, Misaki Yasutake, Ryo Matsumiya, Yutaka Inaba, Yuki Yamamoto, Masatoshi Jinnin, Takao Fujii

    We hypothesized that changes in skin characteristics on the forearm could be useful for early diagnosis of systemic sclerosis (SSc). We used VISIA digital imaging system to investigate this possibility for the first time. Twenty-eight Japanese patients who were diagnosed with typical or very early diagnosis of SSc (VEDOSS) were enrolled in this study, and ten age- and gender-matched patients with other disorders were included as a control group. Eight skin characteristics were analyzed. Our method of evaluating forearm skin characteristics was shown to be reproducible. The scores of WRINKLES, TEXTURE, PORES, and PORPHYRINS were higher in SSc subjects with sclerotic forearm skin (SSc forearm+; 11.004, 5.116, 3.230, and 0.084, respectively) and those without (SSc forearm-: 11.915, 4.898, 2.624, 0.0616, respectively) than in the non-SSc control subjects (10.075, 4.496, 2.459, 0.0223, respectively). Also, the scores of SPOTS, TEXTURE, PORES, UV SPOTS, BROWN SPOTS, and PORPHYRINS were elevated in SSc forearm+ (3.182, 5.116, 3.230, 5.761, 6.704, 0.084, respectively) and SSc forearm- patients (2.391, 4.898, 2.624, 9.835, 5.798, 0.0616, respectively) compared with those with VEDOSS (2.362, 4.738, 2.234, 5.999, 4.898, 0.0169, respectively). We found statistical significance in the difference in score of PORPHYRINS between SSc forearm- and VEDOSS groups (p = 0.044), and between SSc forearm+ and VEDOSS groups (p = 0.012). Therefore, they can be used to differentiate VEDOSS from early or mild SSc cases, which is sometimes clinically problematic. Our study also suggests that the porphyrin research will lead to a better understanding of SSc pathogenesis.

  • Open Access

    Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study

    by Yutaka Inaba, Nobuo Kanazawa, Kyoko Muraoka, Azusa Yariyama, Ami Kawaguchi, Kayo Kunimoto, Chikako Kaminaka, Yuki Yamamoto, Kaoru Tsujioka, Akira Yoshida, et al.

    The patient was a 26-year-old male. He had red and scaling skin of the entire body since birth, as well as an elevated level of serum IgE. Genetic testing revealed a mutation in the SPINK5 gene, which had confirmed the diagnosis with Netherton syndrome. He has had significant pruritis since birth, and subsequently had symptoms of sleeping disorders and concentration difficulty throughout the day. Since treatment with various antihistamines were not effective, we administered dupilumab and found that it was effective in immediate elimination of pruritus and gradual reduction of the rash. Dupilumab has been administered for one year without any adverse events or recurrence of symptoms. Although studies have previously described cases who used dupilumab for Netherton syndrome, reported effects have been limited or transient. Additional studies are needed to confirm the effect of dupilumab for Netherton syndrome, which currently lack any effective treatment strategies.


  • yRNA3 up-regulation in cultured dermal fibroblasts and yRNA4 down-regulation in the sera of scleroderma patients

    by Sayaka Tani, Chikako Kaminaka, Kosuke Nishiyama, Azusa Yariyama, Yumi Nakatani, Yutaka Inaba, Kayo Kunimoto, Yuki Yamamoto, Katsunari Makino, Takamitsu Makino, et al.


  • Open Access

    Effects of low‐dose Aloe sterol supplementation on skin moisture, collagen score and objective or subjective symptoms: 12‐week, double‐blind, randomized controlled trial

    by Chikako Kaminaka, Yuki Yamamoto, Mariko Sakata, Chiaki Hamamoto, Eriko Misawa, Kazumi Nabeshima, Marie Saito, Miyuki Tanaka, Fumiaki Abe, Masatoshi Jinnin

    Daily oral intake of 40 μg Aloe sterol was shown in a double‐blind clinical trial to significantly increase skin barrier function, moisture and elasticity. Ultrasonographic results also suggested that the intake of Aloe sterol increases collagen content in the dermis. Here, we evaluate the effects of a much smaller dose of Aloe sterol, approximately half that used previously, on skin functions in more detail. This is a monocentric, double‐blind, randomized, placebo‐controlled, supplementation study of the effects of low‐dose Aloe sterol on skin transepidermal water loss, hydration, collagen score, evaluation of objective or subjective symptoms, and safety after 12 weeks of daily intake. We randomly administrated either Aloe sterol or placebo to 122 healthy volunteers. Transepidermal water loss was significantly reduced and collagen score was increased in the Aloe sterol group compared with the placebo group at week 12. In the Aloe sterol group, there was significant improvement of objective skin condition (face erythema and pruritus of inner and outer arms) at week 12 compared with week 0, but not in the placebo group. Subjectively, there was significant improvement of visual analog scale of skin acne, fingernail brittleness and constipation in the Aloe sterol group. According to subgroup analysis, although not planned before the study initiation, subjects with dry skin in the Aloe sterol group had significantly increased skin hydration values at week 12 compared with the placebo group. Our results confirmed that even low‐dose Aloe sterol ingestion improves skin moisture by promoting skin barrier function and dermal collagen production, which contributes to maintenance of healthy skin.


  • Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: A prospective, randomized, controlled, split‐area comparative trial

    by Chikako Kaminaka, Naoya Mikita, Yutaka Inaba, Kayo Kunimoto, Hisako Okuhira, Masatoshi Jinnin, Bunsho Kao, Ryuzaburo Tanino, Kensuke Tanioka, Toshio Shimokawa, et al.

    Background and Objectives: Microwave treatment is an effective non‐invasive treatment option for primary axillary hyperhidrosis (PAH), but the treatment parameters vary and no histopathological studies have been performed to validate clinical outcomes. This study investigated its efficacy and safety and histopathological changes after a single microwave treatment at the maximum energy level for PAH in Asians.Materials and Methods: A prospective, clinical, and histological split‐area randomized controlled trial (RCT) was performed in Japan. Twenty‐six subjects underwent a single microwave treatment at the maximum energy level 5 (5.8 GHz/axilla) on the randomized side of axillae. The primary outcome was the mean difference between both sides in the improvement of modified single‐underarm Hyperhidrosis Disease Severity Scale (msHDSS) scores over the course of the 12‐month study period from baseline. The secondary outcomes were; the percentage of responders with at least a 2‐point drop in the msHDSS score of 3 or 4 group or with a 1‐point drop in the msHDSS score of 2 group; the percentage of responders with at least a 75% reduction in sweat weight over 12 months; recurrence rate; and adverse effects. We also performed a histological assessment for 13 selected subjects.Results: Twenty‐four subjects completed the study. There were statistically significant differences in improvement of msHDSS scores between the microwave‐treated and control sides (P < 0.05) from baseline at 0.5, 1, 3, 6, and 12 months. In the msHDSS score of 3 or 4 group, the percentage of responders with at least a 2‐point drop on the microwave‐treated side versus control side was 72.2 versus 11.1% (P < 0.05) at 1 month, 83.3 versus 5.6% (P < 0.05) at 3 months, 61.1 versus 38.9% (P = 0.317) at 6 months and 38.9 versus 16.7% (P = 0.264) at 12 months. The percentage of responders with at least a 75% reduction in sweat weight on the microwave‐treated side versus control side was 75.0 versus 37.5% at 1 month, 75.0 versus 29.2% at 3 months, 83.3 versus 50.0% at 6 months and 70.8 versus 33.3% at 12 months (all P < 0.05). Recurrence on the microwave‐treated side was observed in 4.2% and 12.5% of 24 subjects at 3 and 12 months, respectively. No serious side‐effects were noted. Histology showed the diameter and density of secretory eccrine glands and nerve fiber lengths around eccrine glands were significantly decreased after treatment compared to baseline (P = 0.002, 0.027, 0.003, respectively).Conclusions: A single‐session microwave treatment at the maximum energy level significantly improved the PAH of Japanese patients and had minimal side effects. This technique demonstrates that diminished size of secretory eccrine glands and nerve fiber degeneration could be useful markers for predicting the efficacy of the treatment. Lasers Surg. Med. 9999:1–8, 2019.


  • Long-Term Clinical and Histological Effects of a Bipolar Fractional Radiofrequency System in the Treatment of Facial Atrophic Acne Scars and Acne Vulgaris in Japanese Patients: A Series of Eight Cases

    by Chikako Kaminaka, Fukumi Furukawa, Yuki Yamamoto

    Objective: This retrospective case series was designed to compare the long-term safety and efficacy of bipolar fractional radiofrequency (FRF) therapy as a treatment for atrophic acne scars (ASs) and acne vulgaris. Background data: Few clinical and histological studies have examined the long-term utility of bipolar FRF therapy as a treatment for ASs and acne in people with darker skin. Materials and methods: Eight Japanese patients with ASs and mild-to-severe acne on both cheeks were treated with a bipolar FRF system (eMatrix; Syneron). Five treatment sessions with the same settings (coverage rate: 10%; peak energy: 62 mJ/pin; two passes) were carried out at 1-month intervals, and the patients were followed up for at least 1 year after the final treatment. Assessments of ASs and acne severity were performed and samples were removed for histological examination. Results: We demonstrated that mild ASs responded better than moderate and severe ASs, and at least 50% improvement in scar severity was seen in 50% of patients after the final treatment. Six patients remained disease free at 1.5 years without the use of any additional therapies. The biopsy specimens showed a marked improvement characterized by a decrease in dermal pilosebaceous units and perivascular inflammatory cell infiltrates with an increase in elastin content and collagen deposition in the upper dermis. Conclusions: Bipolar FRF treatment showed long-term effectiveness against mild ASs and acne in Asian patients and had minimal side effects.